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OBJECTIVE: To determine the rate of CVD in asymptomatic
individuals with diabetes mellitus [DM] using non-invasive
myocardial perfusion imaging [MPI]. METHODS: This obser-
vational study identiﬁed individuals with DM [ICD-9-CM
250.0] from an administrative database maintained by VISN 22
[Department of Veterans’ Affairs]; and, patients received all in-
patient and out-patient care from this VISN. One cohort of 53-
year old males consisted of individuals who did not undergo MPI
over a 24-month interval [n = 60]; another cohort included
attribute-matched individuals who had undergone MPI during
the same interval. This group did not undergo MPI due to
ischemia or other clinical ﬁndings of CAD. Evidence of MPI uti-
lization consisted of HCPCS code assignment. Patient records
were examined to identify post-MPI CVD and interval morbid-
ity. RESULTS: Of those who did not undergo MPI, 15% expe-
rienced CVD-related events during the observation interval
including acute MI [n = 7], dysrhythmias, and heart failure;
however, 25% of MPI studies were abnormal in the second
cohort, no patients experienced acute MI, and dysrhythmias and
heart failure occurred in two patients [p < 0.01]. The rate of
CVD events in the ﬁrst cohort is 0.375/month whereas in the
second cohort it is 0.083/month [p < 0.001]. Half of the abnor-
mal MPI studies identiﬁed multi-vessel CAD. Eleven patients
underwent CABG procedures in the second cohort based on ﬁnd-
ings at MPI; none of the non-MPI patients underwent such inter-
vention. CONCLUSIONS: MPI detected CVD in asymptomatic
patients with DM which resulted in appropriate intervention and
improvement in net health outcomes. Up to 22% of individuals
in the US with DM have asymptomatic CVD, and appropriate
use of MPI should be considered in this setting.
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GLYCEMIC RESPONSE TO PIOGLITAZONE THERAPY IN
AFRICAN-AMERICAN AND LATINO PATIENTS WITH 
TYPE-2 DIABETES
Rajagopalan R, Naughten P,Vallarino C
Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA
OBJECTIVE: To compare African-American patients (16% of
the population) and Latino patients (15% of the population) to
their respective complementary cohorts of all other patients
(including 66% Caucasian, and 3% others) in terms of glycemic
response to pioglitazone combination therapy. METHOD:
Twenty-four-week data from three randomized controlled trials,
each using 30- or 45mg doses of pioglitazone combined with i)
sulfonylurea; ii) metformin; or iii) insulin for 24-weeks, were
analyzed. Mean changes from baseline in hemoglobin A1c
between (a) African-Americans and all others and (b) Latinos
and all others were compared using regression models with base-
line demographics and hemoglobin A1c as covariates. RESULTS:
Baseline hemoglobin A1c measurements ranged from 10.11 to
10.86 among African-Americans, from 9.73 to 10.11 among
Latinos, and from 9.57 to 9.89 among all others. The mean
reduction in hemoglobin A1c from baseline was statistically sig-
niﬁcant in every African-American treatment group (-0.96% to
-2.34%) and every Latino treatment group (-1.26% to -1.85%)
as well as the “all others” groups. Signiﬁcantly larger mean
reductions in hemoglobin A1c were detected in African-
Americans than all others in two treatment groups (receiving
higher doses of pioglitazone with sulfonylurea and with met-
formin) and in Latinos in one treatment group (the lower dose
of pioglitazone with metformin combination). Patients with rel-
atively higher baseline hemoglobin A1c and body mass index
measurements tended to beneﬁt more from treatment. CON-
CLUSION: Data from three clinical trials show that African-
Americans and Latinos attained decreases in hemoglobin A1c
levels using pioglitazone combination therapy. Generally, the
improvements in hemoglobin A1c in African-Americans and
Latinos were comparable to the corresponding cohorts of all
others.
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OBJECTIVES: Diabetic patients have increased risk of develop-
ing Alzheimer’s disease (AD). Recent clinical studies have shown
that the use of insulin-response enhancers, (rosiglitazone and
pioglitazone), have improved memory functioning in patients
with mild Alzheimer’s disease. We hypothesized that the use of
glitazones may reduce the risk of AD in diabetic patients.
METHODS: Diabetic patients were identiﬁed from a 20%
sample of California Medicaid claims database from 1995–2002.
Diabetic patients were divided into a glitazone group and a rel-
atively comparable control group that had at least an interclass
switching or combination regimen. Index events were the ﬁrst
glitazone prescription for the experimental group, or the ﬁrst
switching or combination regimen for the control group. Six
months of continuous eligibility were required prior to the index
event, and patients were followed until admission to nursing
home, disenrollment or the end of study period. Patients with
any diagnosis of AD prior to index event were excluded. We used
Cox proportional hazard model to adjust for variable length of
follow-up periods and account for censoring. RESULTS: In total,
16,378 patients in glitazone group and 7313 controls met selec-
tion criteria. Glitazone patients were older (64.1 vs. 54.3 years,
p < 0.0001), had signiﬁcantly higher incidence of each of four-
teen morbidities included (diabetic complications, dementia,
depression, hypertension, CHF, CHD, etc.), and more resource
utilization than control group. However, glitazone patients had
fewer incidence of AD during the follow-up period than the
control group (0.33% vs. 0.62%, p = 0.0016). After controlling
for risk factors, use of glitazone was associated with 55% risk
reduction of developing AD (HR = 0.448, p = 0.01). Additional
analysis revealed no signiﬁcant difference between rosiglitazone
and pioglitazone in risk reduction. CONCLUSIONS: Use of gli-
tazones signiﬁcantly reduced the risk of AD in the study popu-
lation.This implied a preventive utility of glitazones in delaying
the onset of AD in diabetic population.
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TREATMENT PATTERNS IN MANAGEMENT OF TYPE-2
DIABETES WITH CONCURRING COMORBIDITIES
Lipskiy N, Kress A
Surveillance Data Inc, Plymouth Meeting, PA, USA
OBJECTIVE: The goal of this study is to evaluate treatment pat-
terns in the management of type-2 diabetes (T2D) patients, with
coexisting comorbidities, including cardiovascular diseases and
hyperlipidemia. METHODS: In a retrospective cohort study cov-
ering three 12-month periods (2001, 2002 and 2003), we ana-
lyzed the treatment of newly diagnosed T2D patients. We kept
track of records for each cohort in the subsequent 12-months
after the initial diagnosis. The study was based on the analysis
of electronic CMS1500 medical claims for more than 2,466,131
unique patients (HIPAA compliant). The patients’ medication
records were assessed through NCPDP electronic pharmacy
claims utilizing NDC codes and drug classes. RESULTS: Between
2000 and 2003, only 30.8%–35.8% of all patient cohorts did
not have comorbidities. The highest level of comorbidities preva-
lence was discovered within older patients. In 2003, the per-
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centage of patients aged 65–74 years with comorbidities was
52.9% higher than people aged 25–34 years old (p < 0.05). For
all cohorts, regardless of age, one of four patients with T2D coin-
cides with hypertension, one of ten patients with T2D coincides
with hyperlipidemia, and one of three patients with T2D coin-
cides with both hypertension and hyperlipidemia. In 2003, the
frequency of physicians’ visits for T2D patients with hyperten-
sion and hyperlipidemia was 2.3 times higher than for T2D
patients without comorbidities (p < 0.01). In terms of T2D
comorbidities, a major trigger for physicians to prescribe a drug
is the coexistence of both hypertension and hyperlipidemia.
CONCLUSIONS: The analysis of T2D incidence trends demon-
strates that developing disease management strategies for physi-
cians should include in their judgment, the fact that in a majority
of cases, patients have T2D coinciding with cardiovascular dis-
eases and hyperlipidemia.
PDB7
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OBJECTIVE: The goal of this study is to evaluate physicians’
prescribing behavior based on the results of Hb1Ac tests for
patients with type-2 diabetes. METHODS: The study design was
retrospective covering the 12-month longitudinal period June,
2003 through May, 2004. We used a three-month look back
period and a three-month look forward period for the validation
of pre and post test (HbA1c) therapy. The study was based on
the analysis of electronic CMS1500 claims for 33,764 unique
patients (HIPAA compliant) and their results from the most
recent HbA1c tests. Patients’ medication was assessed through
NCPDP electronic claims utilizing NDC codes and drug classes.
Analysis included calculations of descriptive statistics and regres-
sion modeling. RESULTS: The high level of HbA1c was discov-
ered during laboratory testing where a higher percentage of
patients without medication were placed on medication. In par-
ticular, within a category of patients with HbA1c greater than
or equal to 9mg/dL, this switch occurred 32.1% more frequently
then within a category of patients with HbA1c less than 7mg/dL
(p < 0.01). For patients with HbA1c greater than or equal to 9
mg/dL, the likelihood to change an existing therapy was 64.2%
higher than for patients with HbA1c less than 7mg/dL (p < 0.01).
Also, for people with a high level of Hb1Ac, the likelihood to
switch from monotherapy to polytherapy was 1.6 times higher
than for people with a low level of testing. CONCLUSIONS: 
For patients with type-2 diabetes, a level of Hb1Ac is one of 
the important predictors of change in a physician’s prescribing
behavior. High levels of HbA1c most likely will cause a switch
from just a dietary and exercise regimens to additional medica-
tion component.
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PATTERNS BASED ON CLASSIFICATION OF BODY MASS
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OBJECTIVES: To examine trends of diabetes mellitus (DM)
prevalence in adults and to investigate treatment patterns and
HbA1c control according to their body mass index (BMI) clas-
siﬁcation. METHODS: This study used the Third National
Health and Nutrition Examination Survey (NHANES III for
1988–1994) and NHANES 2001–2002, representing a national
sample of the non-institutionalized civilian US population. Study
patients were identiﬁed if they were ≥20 years old, were previ-
ously diagnosed with DM by a physician or is currently using
DM therapy (insulin or a hypoglycemic agent). DM patients
were classiﬁed as normal (BMI < 25), overweight (BMI: 25–29),
or obese (BMI ≥ 30). Data were analyzed using SAS and
SUDAAN statistical software. RESULTS: The age-adjusted
prevalence of DM signiﬁcantly increased from 5.4% in
1988–1994 to 7.1% in 2001–2002 (increase of 1.7%: p < 0.05).
In 2001–2002, DM was more prevalent in overweight patients
(6.1%) and obese patients (10.5%) than in normal weight
patients (4%). These trends were similar in 1988–1994. More
DM patients (80% of overweight and 87% of obese patients)
received treatment in 2001–2002 than during 1988–1994 (70%
and 78%) (increases: p = 0.05 respectively). Patients were treated
with oral antihyperglycemics only most frequently (56%), fol-
lowed by insulin only (17%), and with both insulin and an oral
agent (9%). Overall, mean HbA1c decreased from 7.7% (57%
of DM-patients: HbA1c ≥ 7%) in 1988–1994 to 7.5% (50% of
DM-patients: HbA1c ≥ 7%) in 2001–2002 (p = 0.24). CON-
CLUSIONS: Over the past decade, DM has become more preva-
lent in US adults, more overweight and obese DM patients have
received treatment, yet 20% of overall DM patients still have not
received treatment. In 2001–2002, half of diabetic patients did
not control their HbA1c level and diabetic patients who were
obese were less likely to control their HbA1c compared to
patients who were normal weight.
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HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO
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OBJECTIVES: To investigate the association between a lower
A1c (a measure of better diabetes control) and multiple health
system and individual variables in a Latino population.
METHODS: Data were obtained from the Los Angeles Latino
Eye Study (LALES) and included 6980 participants who were
>40 years old. Subjects with a physician diagnosis and those
without were stratiﬁed and compared. Continuous variables
were summarized using means, standard deviations and T-tests.
Categorical variables were summarized using frequency tables
and Chi-square tests. Multivariate linear regression was per-
formed on subjects with diabetes. P-value less than 0.05 were
considered statistically signiﬁcant. RESULTS: There were 1095
subjects with DM resulting in a prevalence of 18%, 73.0% of
subjects were married or living with their partner, 43.4% of 
subjects were males, 65.9% of subjects had insurance coverage,
and 3.8% of the subjects without a diagnosis had A1c values
that were above the diabetic goal, indicating probable diabetes
disease. Diabetics were older than non-diabetics (57.8 vs. 53.9;
p < 0.0001), insured (73.9% vs. 64.2%; p < 0.0001) and had a
higher percentage of individuals with a household income less
than $20,000 (55.8% vs. 49.6%; p = 0.0002). In total, 57.4%
of diabetics were using oral anti-diabetic medication alone, 5.9%
were using insulin alone, 3.6% were using diet alone and 15.3%
were using a combination of oral medication and insulin. Mul-
tivariate linear regression analysis (R2 = 0.1225, p < 0.0001)
showed that being older, single, insured, male and a lower
income was associated with a lower A1c. Also fewer disease
years, higher BMI, on diet vs. combination treatment were asso-
ciated with a lower A1c. How much the subjects have adopted
the American culture, expressed as an acculturation score, was
not signiﬁcantly associated with A1c. CONCLUSIONS: Though
this study did not measure severity of disease and medication
